Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Kalaris Therapeutics, Inc. from 31 Dec 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Kalaris Therapeutics, Inc. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Dec 2019 to 31 Mar 2025.
  • Kalaris Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Mar 2025 was $99,826,000, a 4751% increase year-over-year.
  • Kalaris Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $27,316,000.
  • Kalaris Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $15,971,000, a 83% increase from 2022.
  • Kalaris Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $95,569,000, a 220% decline from 2021.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

Kalaris Therapeutics, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $99,826,000 +$97,768,000 +4751% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2024 $2,058,000 -$7,548,000 -79% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q1 2023 $9,606,000 +$111,061,000 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q1 2022 $101,455,000 -$147,439,000 -321% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q1 2021 $45,984,000 +$42,688,000 +1295% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q1 2020 $3,296,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1

Kalaris Therapeutics, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $27,316,000 +$43,287,000 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
2023 $15,971,000 +$79,598,000 +83% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
2022 $95,569,000 -$175,421,000 -220% 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024 2023 FY
2021 $79,852,000 +$18,275,000 +30% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2023 2022 FY
2020 $61,577,000 +$25,453,000 +70% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2022 2021 FY
2019 $36,124,000 01 Jan 2019 31 Dec 2019 10-K 12 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.